2 Reasons to Sell Merck Stock and 1 Reason to Buy

There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates consistent revenue and profits, has a deep pipeline, and pays a regular dividend.These are all good things, none of which has stopped the company's shares from significantly underperforming broader equities this year. Merck's shares are down by 8% year to date. What's going on with the healthcare giant?Let's consider two reasons investors might be right to sell off Merck's stock and one reason the drugmaker could still be an excellent long-term investment.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool